AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...

Humira is used to treat certain inflammatory conditions. It’s mainly covered by Medicare Part D when self-administered or, more rarely, by Part B when administered by a doctor. Humira ...

The availability of Humira biosimilars potentially affects a vast number of patients and healthcare professionals. Our team of clinicians explored all of the different biosimilars set to enter the ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event for a number of reasons, not least because the drug is the top-selling pharmaceutical product of all ...

It might be 11:11 or 3:33. Maybe repeating numbers have made their way into other aspects of your life, such as a receipt that totaled $22.22. These may seem like mere coincidences ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

This was, of course, still driven by its blockbuster product Humira. Biotechnology is becoming more and more the leading technology within the pharmaceutical industry. Seven out of the ten most ...

It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (SNPINDEX ...

Why is it necessary to pay attention to this franchise? The answer is quite simple and lies in the fact that sales of Humira, Skyrizi, and Rinvoq accounted for about 48% of its total revenue for ...